Toronto AI Startup Biossil Raises $70M to Resurrect Failed Drug Candidates Using Large Language Models
核心洞察
Biossil (搜索), founded by University of Toronto alumni, has secured $70 million in funding from Peter Thiel's Founders Fund (搜索) and OpenAI (搜索) to revive abandoned pharmaceutical compounds using AI technology.
The company has acquired 10 failed drug molecules and advanced two into late-stage clinical trials, with three more seeking regulatory approval for market entry.
Biossil (搜索)'s AI platform analyzes publicly available data from failed trials to identify overlooked therapeutic opportunities, potentially saving years of development time and hundreds of millions in costs.
A Toronto-based artificial intelligence startup has emerged from stealth mode with a novel approach to drug development that could reshape how the pharmaceutical industry approaches failed clinical trials. Biossil (搜索) Inc., founded in 2023 by University of Toronto alumni Anthony Mouchantaf and Dr. Alexander Mosa, has raised approximately $70 million to resurrect abandoned drug candidates using large language models.
The company has quietly assembled a portfolio of 10 drug molecules previously discarded by major pharmaceutical companies, with two currently in advanced clinical trials and three more preparing for regulatory approval. "We've very quietly become the most advanced drug developer of this AI era, bar none," said Mouchantaf, the company's CEO and former head of Royal Bank of Canada's venture capital investment strategy.
Revolutionary AI-Driven Drug Repurposing Platform
Unlike other AI drug development companies that focus on designing new molecules from scratch, Biossil (搜索) employs a fundamentally different strategy. The company uses OpenAI (搜索)'s large language models to analyze publicly available information about failed drug candidates, including research data, press releases, and securities filings, to identify overlooked therapeutic opportunities.
Biossil (搜索)'s AI platform converts textual descriptions of drug attributes into numerical vectors, then maps these against genetic data associated with various diseases. By analyzing the distances between these data points, the system can predict which abandoned drugs might be effective for specific patient populations or disease characteristics.
"It seemed there was an opportunity to mine this reservoir of drugs that had failed despite passing safety and early efficacy studies, identify the ones with the most commercial promise, and pick up where their previous owners had left off," explained Dr. Mosa, who trained as an internal medicine specialist before co-founding the company.
Silicon Valley Backing and Strategic Partnerships
The startup's ambitious vision has attracted significant investment from prominent venture capital firms. Peter Thiel's Founders Fund (搜索) led a $22 million financing round in 2024, followed by a $43 million round co-led with OpenAI (搜索) in late 2024. The company is now valued at more than $100 million.
"The thesis is highly ambitious but grounded in a practical understanding of how value is actually created in drug development," said Founders Fund (搜索) partner Amin Mirzadegan. OpenAI (搜索) Startup Fund partner Ian Hathaway noted that "Biossil (搜索)'s approach to realizing this vision stood out to us immediately, not only for its creativity and ambition, but for its credible path to delivering new therapies."
Biossil (搜索) has established partnerships with more than 20 universities and research hospitals across Canada, the United States, and Europe, including Toronto's Hospital for Sick Children (搜索), Harvard University, the Mayo Clinic, and Denmark's Aarhus University.
Breakthrough Results in Sickle Cell Disease
The company's most advanced programs target sickle cell disease (搜索), a debilitating genetic condition that predominantly affects people of African or Indian descent. Biossil (搜索) has acquired two drug candidates previously abandoned by Johnson & Johnson and Pfizer after failed late-stage trials.
The first molecule, Senicapoc, originally developed with Johnson & Johnson, failed to demonstrate significant pain relief in clinical trials. However, Biossil (搜索)'s AI analysis revealed that the drug was highly effective at preventing red blood cell breakdown, which causes anemia (搜索) and other serious complications in sickle cell patients.
"That tells us the endpoint chosen in retrospect was mistaken," said Dr. Isaac Odame, head of hematology and oncology at Toronto's Hospital for Sick Children (搜索) and a Biossil (搜索) adviser. The company obtained Health Canada approval in 2025 to study Senicapoc's impact on red blood cell breakdown in a late-stage human trial.
The second candidate, Rivipansel, was originally developed by Pfizer to unblock pain-inducing clogged blood vessels (搜索). Biossil (搜索)'s technology revealed that the drug worked significantly better when administered within 24 hours of symptom onset. Because some patients in the original failed trial received treatment later, overall results were compromised.
Armed with this refined understanding, Biossil (搜索) is seeking conditional approval from Health Canada to bring the former Pfizer drug to market and has obtained FDA approval for a confirmatory late-stage trial focusing on the optimal treatment window.
Clinical Validation and Expert Endorsement
The company's approach has gained credibility within the medical community. Dr. Kevin Kuo, a sickle cell expert with Toronto General Hospital, joined Biossil (搜索) as head of medical after being impressed by the platform's analytical capabilities.
"I was amazed when I learned Biossil (搜索)'s methods could uncover insights that rivalled what I had learned during my two-plus decades in the field," said Dr. Kuo. "This to me is proof this technique works with other diseases as well. I'm doing this purely out of conviction."
Economic and Strategic Advantages
Biossil (搜索)'s approach offers significant economic advantages over traditional drug development. Mouchantaf estimated that the previous owners of molecules in Biossil's portfolio had spent more than $1 billion developing the drugs before abandoning them. By acquiring these assets and leveraging existing safety and early efficacy data, the company can potentially bypass years of preclinical and early-stage clinical development.
The founders emphasize their focus on treatments for unmet medical needs in underserved populations, with the goal of bringing new medicines to market more cost-effectively and at lower prices for patients.
As the pharmaceutical industry grapples with rising development costs and high failure rates, Biossil (搜索)'s AI-driven approach to drug repurposing represents a potentially transformative model for extracting value from the industry's substantial investment in failed clinical programs.